Quick Answer
OCULAR THERAPEUTIX, INC reported Total Revenue of $51.95 million for fiscal year 2025.
OCULAR THERAPEUTIX, INC — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $51.95M -18.5% |
$63.72M +9.0% |
$58.44M +13.5% |
$51.49M +18.3% |
$43.52M +150.1% |
$17.40M +311.7% |
| Revenue (ASC 606) | $51.95M -18.5% |
$63.72M +9.0% |
$58.44M +13.5% |
$51.49M +18.3% |
$43.52M +150.1% |
$17.40M +311.7% |
| Net Income | -$265.94M -37.4% |
-$193.51M -139.7% |
-$80.74M -13.7% |
-$71.04M -984.1% |
-$6.55M +95.8% |
-$155.64M -80.2% |
| Diluted EPS | -$1.42 -16.4% |
-$1.22 -19.6% |
-$1.02 -5.2% |
-$0.97 +1.0% |
-$0.98 +61.7% |
-$2.56 -34.0% |
| Total Assets | $808.06M +76.5% |
$457.94M +81.7% |
$252.06M +68.8% |
$149.29M -27.1% |
$204.89M -21.8% |
$261.86M +232.6% |
| Cash and Equivalents | $737.06M +88.0% |
$392.10M +100.2% |
$195.81M +91.4% |
$102.30M -37.7% |
$164.16M -28.0% |
$228.06M +318.9% |
| Stockholders Equity | $654.31M +107.5% |
$315.34M +246.0% |
$91.13M +157.6% |
$35.38M -59.8% |
$88.00M +15.6% |
$76.09M +2196.3% |
| R&D Expense | $197.10M +54.4% |
$127.64M +109.0% |
$61.05M +14.2% |
$53.46M +6.7% |
$50.08M +74.5% |
$28.69M -30.2% |
| Operating Income | -$270.02M -57.2% |
-$171.78M -108.5% |
-$82.38M -4.7% |
-$78.65M -0.8% |
-$78.04M -24.2% |
-$62.85M +26.8% |
| Shares Outstanding | 215.93M +36.9% |
157.75M +37.2% |
114.96M +48.9% |
77.20M +0.6% |
76.73M +1.0% |
76.00M +51.0% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $14.54M | -5.7% | +8.1% |
| Revenue (ASC 606) | September 30, 2025 | $14.54M | -5.7% | +8.1% |
| Net Income | September 30, 2025 | -$69.42M | -90.2% | -2.4% |
| Diluted EPS | September 30, 2025 | -$0.38 | -72.7% | +2.6% |
| Total Assets | September 30, 2025 | $410.88M | -16.2% | -9.0% |
| Cash and Equivalents | September 30, 2025 | $344.77M | -19.3% | -11.9% |
| Stockholders Equity | September 30, 2025 | $258.23M | -26.6% | -15.6% |
| R&D Expense | September 30, 2025 | $52.36M | +41.3% | +2.5% |
| Operating Income | September 30, 2025 | -$68.70M | -49.3% | -1.6% |
| Shares Outstanding | September 30, 2025 | 174.95M | +11.7% | +1.2% |
- OCULAR THERAPEUTIX, INC reported Total Revenue of $51.95 million for fiscal year 2025.
- OCULAR THERAPEUTIX, INC showed a decrease of -18.5% in Total Revenue compared to the prior fiscal year.
- OCULAR THERAPEUTIX, INC reported Revenue (ASC 606) of $51.95 million for fiscal year 2025.
- OCULAR THERAPEUTIX, INC showed a decrease of -18.5% in Revenue (ASC 606) compared to the prior fiscal year.
- OCULAR THERAPEUTIX, INC reported Net Income of -$265.94 million for fiscal year 2025.
- OCULAR THERAPEUTIX, INC showed a decrease of -37.4% in Net Income compared to the prior fiscal year.
- OCULAR THERAPEUTIX, INC reported Diluted EPS of $1.42 per share (loss) for fiscal year 2025.
- OCULAR THERAPEUTIX, INC showed a decrease of -16.4% in Diluted EPS compared to the prior fiscal year.
- OCULAR THERAPEUTIX, INC reported Total Assets of $808.06 million for fiscal year 2025.
- OCULAR THERAPEUTIX, INC showed an increase of +76.5% in Total Assets compared to the prior fiscal year.
- OCULAR THERAPEUTIX, INC reported Cash and Equivalents of $737.06 million for fiscal year 2025.
- OCULAR THERAPEUTIX, INC showed an increase of +88.0% in Cash and Equivalents compared to the prior fiscal year.
- OCULAR THERAPEUTIX, INC reported Stockholders Equity of $654.31 million for fiscal year 2025.
- OCULAR THERAPEUTIX, INC showed an increase of +107.5% in Stockholders Equity compared to the prior fiscal year.
- OCULAR THERAPEUTIX, INC reported R&D Expense of $197.10 million for fiscal year 2025.
- OCULAR THERAPEUTIX, INC showed an increase of +54.4% in R&D Expense compared to the prior fiscal year.
- OCULAR THERAPEUTIX, INC reported Operating Income of -$270.02 million for fiscal year 2025.
- OCULAR THERAPEUTIX, INC showed a decrease of -57.2% in Operating Income compared to the prior fiscal year.
- OCULAR THERAPEUTIX, INC reported Shares Outstanding of 215.93 million shares for fiscal year 2025.
- OCULAR THERAPEUTIX, INC showed an increase of +36.9% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: